Gut microbiota in nonalcoholic fatty liver disease: a PREDIMED-Plus trial sub analysis.
Ana María Gómez-PérezPatricia Ruiz-LimónJordi Salas-SalvadóJesús VioqueDolores CorellaMontse FitóJosep VidalAlessandro AtzeniLaura Torres-ColladoAndrea Álvarez-SalaMaría Ángeles MartínezAlbert GodayDavid BenaigesJesús García-GavilánMaría Rosa Bernal LópezIsabel Moreno-IndiasFrancisco J TinahonesPublished in: Gut microbes (2023)
To evaluate the changes in the gut microbiota associated with changes in the biochemical markers of nonalcoholic fatty liver disease (NAFLD) after a lifestyle intervention with the Mediterranean diet. Participants ( n = 297) from two centers of PREDIMED-Plus trial (Prevención con Dieta Mediterránea) were divided into three different groups based on the change tertile in the Hepatic Steatosis Index (HSI) or the Fibrosis-4 score (FIB-4) between baseline and one year of intervention. One-year changes in HSI were: tertile 1 (T1) (-24.9 to -7.51), T2 (-7.5 to -1.86), T3 (-1.85 to 13.64). The most significant differences in gut microbiota within the year of intervention were observed in the T1 and T3. According to the FIB-4, participants were categorized in non-suspected fibrosis (NSF) and with indeterminate or suspected fibrosis (SF). NSF participants showed higher abundances of Alcaligenaceae , Bacteroidaceae , Bifidobacteriaceae , Clostridiaceae , Enterobacteriaceae , Peptostreptococcaceae , Verrucomicrobiaceae compared to those with SF. Then, participants were divided depending on the FIB-4 tertile of change: T1 (-89.60 to -5.57), T2 (-5.56 to 11.4), and T3 (11.41 to 206.24). FIB-4 T1 showed a decrease in Akkermansia and an increase in Desulfovibrio . T2 had an increase in Victivallaceae , Clostridiaceae , and Desulfovibrio . T3 showed a decrease in Enterobacteriaceae , and an increase in Sutterella , Faecalibacterium , and Blautia . A relation between biochemical index changes of NAFLD/NASH (HSI and FIB-4) and gut microbiota changes were found. These observations highlight the importance of lifestyle intervention in the modulation of gut microbiota and the management of metabolic syndrome and its hepatic manifestations.